A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
- 1 May 1986
- Vol. 57 (9), 1725-1730
- https://doi.org/10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j
Abstract
A randomized clinical trial was conducted in women with bulky (suboptimal) Stage III and Stage IV ovarian carcinoma, using doxorubicin (Adriamycin) and cyclophosphamide with or without cisplatin. There were 440 evaluable cases, of which 227 had measurable disease. One hundred twenty of these latter patients were treated with cyclophosphamide and doxorubicin (CA), while 107 received cyclophosphamide, doxorubicin and cisplatin (CAP). The clinical complete response (CR) rate for CA was 26% (31/120) compared with 51% (55/107) for CAP (P = versus 8.8 months), progression-free interval for all patients (13.1 versus 7.7 months), and survival for patients with measurable disease (19.7 versus 15.7 months) showed a statistically significant advantage for CAP; however, there was no difference in survival of patients with nonmeasurable disease. Toxicity was more severe with CAP but was tolerable. Thus, the addition of cisplatin improves the chemotherapy of advanced ovarian carcinoma.Keywords
This publication has 9 references indexed in Scilit:
- Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovaryAmerican Journal of Clinical Oncology, 1983
- Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdensCancer, 1983
- Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1983
- A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinomaCancer, 1983
- Acute Nonlymphocytic Leukemia after Therapy with Alkylating Agents for Ovarian CancerNew England Journal of Medicine, 1982
- Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)Cancer, 1981
- RANDOMISED TRIAL COMPARING LOW-DOSE CISPLATIN AND CHLORAMBUCIL WITH LOW-DOSE CISPLATIN, CHLORAMBUCIL, AND DOXORUBICIN IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1981
- Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycinCancer, 1980
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978